3 results
Approved WMOCompleted
Primary Objective To evaluate long term safety and tolerability of LAI (590 mg) administered once daily (QD) for up to 12 months in subjects who were refractory to standard multi-drug treatment and failed to convert in Study INS-212. Secondary…
Approved WMOPending
Evaluate the effect of pediatric asthma eHealth care on the healthcare utilization, asthma outcomes and quality of life.
Approved WMORecruiting
Primary objective: - To investigate the effect of additional levamisole in comparison with placebo from 4 weeks to 6 months after the start of the first episode of steroid-sensitive INS in children (age 2 - 16 years) on the occurrence of relapses…